Michelle Saad

Dr. Michelle Saad

Cincinnati Children's Hospital Medical Center, Cincinnati

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2023 in Pancreatology
Verified
Journal Article
Closed access
Michelle SaadMichelle Saad
Michelle Saad
DVDavid S. Vitale
David S. Vitale
TLTom K. Lin
Tom K. Lin
STSamjhana Thapaliya
Samjhana Thapaliya
YZYuan Zhou
Yuan Zhou
MAMaisam Abu-El-Haija
Maisam Abu-El-Haija

1 October 2024 in Abdominal Radiology
Verified
Journal Article
Open access
PDF file
PDPradipta Debnath
Pradipta Debnath
JTJean Tkach
Jean Tkach
Michelle SaadMichelle Saad
Michelle Saad
DVDavid S. Vitale
David S. Vitale
MAMaisam A. Abu-El-Haija
Maisam A. Abu-El-Haija
ATAndrew T. Trout
Andrew T. Trout
Purpose: Our primary purpose was to understand the correlation between pancreas T1-weighted signal intensity ratio (SIR) and T1 relaxation time in children. We also sought to characterize differences in T1 SIR between children without and with pancreatitis. Methods: Retrospective study of patients < 18-years-old. SIR-pancreas:spleen (SIR-PS) and SIR-pancreas:paraspinal muscle (SIR-PM) were generated from T1-weighted gradient recalled echo images. Subdivided by field strength, T1 SIR was correlated (Spearman’s) with T1 relaxation time. Results: 220 participants were included, 144 imaged at 1.5T (mean: 11.4 ± 4.2 years) and 76 imaged at 3T (mean: 10.9 ± 4.5 years). At 1.5T, SIR-PS (rho=-0.62, 95% CI: -0.71 to -0.51, p < 0.0001) and SIR-PM (rho=-0.57, 95% CI: -0.67 to -0.45, p < 0.0001) moderately negatively correlated with T1 relaxation time. At 3T, correlations between T1 SIR and T1 relaxation time were moderate (rho=-0.40 to -0.43, p ≤ 0.0003). SIR-PS was significantly different between patient groups at 1.5T (p < 0.0001) with pairwise differences between: normal vs. acute on chronic pancreatitis (1.52 vs. 1.13; p < 0.0001). SIR-PM was also significantly different between groups at 1.5T (p < 0.0001) with differences between: normal vs. acute pancreatitis (1.65 vs. 1.40; p = 0.0006), normal vs. acute on chronic pancreatitis (1.65 vs. 1.18; p < 0.0001), and normal vs. chronic pancreatitis (1.65 vs. 1.52; p = 0.0066). A SIR-PS cut-off of ≤ 1.31 had 44% sensitivity and 95% specificity and SIR-PM cut-off of ≤ 1.53 had 69% sensitivity and 70% specificity for pancreatitis. At 3T, SIR-PS was significantly different between groups (p = 0.033) but without significant pairwise differences. Conclusion: At 1.5T pancreas T1 SIR moderately to strongly correlates with estimated T1 relaxation time and is significantly lower in children with pancreatitis.

17 December 2020 in Children
Verified
Journal Article
Open access
PDF file
Michelle SaadMichelle Saad
Michelle Saad
SSSabeen Syed
Sabeen Syed
MAHEEN ILYASMAHEEN ILYAS
MAHEEN ILYAS
AGAnatoliy A. Gashev
Anatoliy A. Gashev
The prevalence of childhood obesity has increased over the years in the United States and contributed to a rise in metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). Animal studies suggested the role of histamine blockade on mesenteric lymphatics tone, contributing to weight gain and hepatic steatosis. This study aimed to investigate an association between antihistamines (AH) use in children and obesity. A single-center retrospective cohort study on children with a diagnosis of NAFLD, followed in the gastroenterology clinic, was performed between January 2018 and April 2019. The demographics, medications, and body mass index (BMI) were assessed. Participants were divided into an AH group with documented use and comparison group, antihistamine naïve. Of the 32 participants in the study, 13 used AH, and 19 did not. Antihistamine users had a mean increase in BMI percentile per year of 1.17 compared to a decrease of 0.06 in comparison group (p = 0.0008). AH usage correlated with a mean increase in BMI z-score of 0.23 per year, as opposed to a decrease by 0.012 in comparison group (p = 0.0016). No difference was found in triglycerides (TG), glucose, and liver enzymes. AH use increases BMI percentiles and z-scores over time and is associated with obesity in children.

9 August 2023 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
KZKe-You Zhang
Ke-You Zhang
ISIsmaeel Siddiqi
Ismaeel Siddiqi
Michelle SaadMichelle Saad
Michelle Saad
TBTatiana Balabanis
Tatiana Balabanis
MDMelody S. Dehghan
Melody S. Dehghan
ZSZachary M. Sellers
Zachary M. Sellers
INTRODUCTION: Pancreatitis in inflammatory bowel disease has been attributed to peripancreatic intestinal disease and/or drug-induced pancreatic toxicity. We used large cohort analyses to define inflammatory bowel disease and pancreatitis temporal co-occurrence with a detailed descriptive analysis to gain greater insight into the pathophysiological relationship between these 2 diseases. METHODS: Truven Health MarketScan private insurance claims from 141,017,841 patients (younger than 65 years) and 7,457,709 patients from 4 academic hospitals were analyzed. We calculated the prevalence of Crohn's disease or ulcerative colitis (UC) with acute pancreatitis or chronic pancreatitis (CP) and performed temporal and descriptive analyses. RESULTS: Of 516,724 patients with inflammatory bowel disease, 12,109 individuals (2.3%) had pancreatitis. Acute pancreatitis (AP) was 2–6x more prevalent than CP. In adults, AP occurred equally among Crohn's disease and UC (1.8%–2.2% vs 1.6%–2.1%, respectively), whereas in children, AP was more frequent in UC (2.3%–3.4% vs 1.5%–1.8%, respectively). The highest proportion of pancreatitis (21.7%–44.7%) was at/near the time of inflammatory bowel disease diagnosis. Of them, 22.1%–39.3% were on steroids during pancreatitis. Individuals with CP or recurrent pancreatitis hospitalizations had increased risk of a future inflammatory bowel disease diagnosis (odds ratio = 1.52 or 1.72, respectively). DISCUSSION: Pancreatitis in inflammatory bowel disease may not simply be a drug adverse event but may also involve local and/or systemic processes that negatively affect the pancreas. Our analysis of pancreatitis before, during, and after inflammatory bowel disease diagnosis suggests a bidirectional pathophysiologic relationship between inflammatory bowel disease and pancreatitis, with potentially more complexity than previously appreciated.

12 August 2024 in JPGN Reports
Verified
Journal Article
Open access
Michelle SaadMichelle Saad
Michelle Saad
MAMaisam Abu‐El‐Haija
Maisam Abu‐El‐Haija
TLTom K. Lin
Tom K. Lin
ATAlexander J. Towbin
Alexander J. Towbin
ATAndrew T. Trout
Andrew T. Trout
DVDavid S. Vitale
David S. Vitale
Management of choledochoceles (type III choledochal cysts) in children varies. We highlight the potential role of endoscopic management of choledochoceles with cystostomy and biliary sphincterotomy through a series of three successfully treated pediatric patients aged 12–13 at our tertiary center. Patients presented with symptoms including abdominal pain and pancreatitis. Choledochoceles were identified by preprocedure imaging on magnetic resonance imaging, with sizes ranging between 7 and 15 mm in maximal diameter. Histology revealed two choledochoceles lined by biliary epithelium and one by intestinal epithelium. Clinical improvement was sustained at a 2‐year follow‐up, with radiographic resolution on repeat imaging and normal tumor markers. We conclude that endoscopic management of choledochoceles with cystostomy and biliary sphincterotomy is a therapeutic option in children and can lead to sustained resolution of associated symptoms. While there is some lifetime risk of malignancy with choledochal cysts, malignancy in choledochoceles is rare.

28 January 2026 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
MMMadalyn G. Moore
Madalyn G. Moore
VGVineet Garlapally
Vineet Garlapally
KBKatelyn B. Brusach
Katelyn B. Brusach
VAVenkata Akshintala
Venkata Akshintala
LBLynn Babcock
Lynn Babcock
MAMaisam A. Abu-El-Haija
Maisam A. Abu-El-Haija
INTRODUCTION: Reliable biomarkers for the diagnosis of chronic pancreatitis (CP) and pancreatic fibrosis severity are lacking, hindering effective treatment and management. Histologic fibrosis is a hallmark of late-stage CP, but noninvasive methods to evaluate fibrosis progression are limited. We used urine proteomics to discover biomarkers that identify patients with CP and predict fibrosis severity. METHODS: We performed a cross-sectional study of 130 total subjects (CP n = 50) selected based on clinical criteria in a tertiary care setting. Urine proteomics samples were quantified using data-independent acquisition mass spectrometry. Differential biomarker candidates were identified with false discovery rate-corrected pairwise comparisons. These proteins were validated with an independent paired urine and plasma sample cohort (n = 36). Machine learning was used to develop a protein panel that predicted Ammann scores for patients with histologic fibrosis. RESULTS: We found 34 proteins consistently differentially expressed between CP and controls in pairwise false discovery rate-controlled tests. Of these, 25 urine proteins outperformed 19 previously suggested CP blood-based biomarkers in an independent validation cohort. Isocitrate dehydrogenase (IDH1), calcyphosin (CAPS), synuclein gamma (SNCG), and protein S100-P (S100P) all produced receiver operator curve area under the curve values >0.95, while the best plasma marker was interleukin 2 receptor subunit alpha (receiver operator curve area under the curve = 0.80). A 12-protein panel of identified markers predicted fibrosis severity with a linear correlation R 2 value of 0.61. DISCUSSION: We identified a panel of proteins that may diagnose CP in children and developed a model to predict pancreatic fibrosis severity, offering promising tools for improving diagnostics and patient care.